T1	Participants 67 101	women treated with soy isoflavones
T2	Participants 182 247	women who do and who do not produce equol, a daidzein metabolite.
T3	Participants 255 378	A randomized, double-blind, placebo-controlled clinical trial was conducted over 6 months with 96 healthy menopausal women.
T4	Participants 441 588	women in the study group were assigned to the equol-producing (EP) or the non-EP group according to the presence or absence of equol in their urine
T5	Participants 922 1025	Isoflavone supplementation improves menopausal symptoms only in women with the ability to produce equol
